X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (84) 84
heart failure - drug therapy (78) 78
heart failure (56) 56
male (56) 56
female (52) 52
heart failure - mortality (52) 52
aged (51) 51
middle aged (47) 47
cardiac & cardiovascular systems (41) 41
mortality (32) 32
heart failure - physiopathology (30) 30
treatment outcome (29) 29
hospitalization (24) 24
index medicus (24) 24
cardiac and cardiovascular systems (23) 23
kardiologi (23) 23
prognosis (23) 23
morbidity (20) 20
survival (20) 20
double-blind method (19) 19
drug therapy (18) 18
angiotensin-converting enzyme inhibitors - therapeutic use (17) 17
adrenergic beta-antagonists - therapeutic use (16) 16
adult (14) 14
chronic disease (14) 14
risk factors (14) 14
heart failure - complications (13) 13
tetrazoles - therapeutic use (13) 13
aged, 80 and over (12) 12
follow-up studies (12) 12
heart attacks (12) 12
proportional hazards models (12) 12
randomized controlled trials as topic (12) 12
therapy (12) 12
benzimidazoles - therapeutic use (11) 11
heart (11) 11
survival analysis (11) 11
cardiotonic agents - therapeutic use (10) 10
kaplan-meier estimate (10) 10
medicine, general & internal (10) 10
survival rate (10) 10
tetrazoles/therapeutic use (10) 10
benzimidazoles/therapeutic use (9) 9
candesartan (9) 9
cardiovascular agents - therapeutic use (9) 9
diagnosis (9) 9
diseases (9) 9
heart failure - diagnosis (9) 9
left-ventricular dysfunction (9) 9
time factors (9) 9
trial (9) 9
adrenergic beta-antagonists/therapeutic use (8) 8
cardiac patients (8) 8
cardiovascular disease (8) 8
health aspects (8) 8
heart rate (8) 8
hospitalization - statistics & numerical data (8) 8
myocardial-infarction (8) 8
outcomes (8) 8
patient outcomes (8) 8
randomized-trial (8) 8
risk (8) 8
abridged index medicus (7) 7
angiotensin ii type 1 receptor blockers - therapeutic use (7) 7
carbazoles - therapeutic use (7) 7
cause of death (7) 7
congestive heart failure (7) 7
death (7) 7
dose-response relationship, drug (7) 7
heart failure - therapy (7) 7
hospitalization/statistics & numerical data (7) 7
metoprolol - therapeutic use (7) 7
pharmacology & pharmacy (7) 7
propanolamines - therapeutic use (7) 7
angiotensin ii type 1 receptor blockers/therapeutic use (6) 6
animals (6) 6
cardiovascular diseases (6) 6
drug therapy, combination (6) 6
electrocardiography (6) 6
epidemiology (6) 6
heart failure/drug therapy/mortality (6) 6
management (6) 6
metoprolol/therapeutic use (6) 6
prospective studies (6) 6
research (6) 6
retrospective studies (6) 6
severity of illness index (6) 6
80 and over (5) 5
acute myocardial-infarction (5) 5
age factors (5) 5
antihypertensive agents - therapeutic use (5) 5
benzazepines - therapeutic use (5) 5
beta-blockers (5) 5
captopril (5) 5
carbazoles/therapeutic use (5) 5
cardiology (5) 5
cardiovascular (5) 5
cardiovascular agents (5) 5
care and treatment (5) 5
carvedilol (5) 5
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (10) 10
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Markham Stouffville Hospital - Stacks (1) 1
Providence Healthcare - Reference (1) 1
Providence Healthcare - Reserve desk (1) 1
Scarborough Hospital - Birchmount (1) 1
Scarborough Hospital - General (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9744, pp. 875 - 885
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2011, Volume 364, Issue 1, pp. 11 - 21
In this trial, 2737 patients with heart failure and LV systolic dysfunction were given eplerenone or placebo in addition to recommended therapy. Eplerenone... 
SURVIVAL | TRIAL | LEFT-VENTRICULAR DYSFUNCTION | TASK-FORCE | SPIRONOLACTONE | ACUTE MYOCARDIAL-INFARCTION | ALDOSTERONE | CARDIAC FIBROSIS | ASSOCIATION | UMCG Approved | MINERALOCORTICOID RECEPTOR | MEDICINE, GENERAL & INTERNAL | ACTIVATION | MYOCARDIAL-INFARCTION | COLLABORATION | CANDESARTAN | Double-Blind Method | Follow-Up Studies | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Hospitalization - statistics & numerical data | Mineralocorticoid Receptor Antagonists - adverse effects | Male | Combined Modality Therapy | Heart Failure - drug therapy | Mineralocorticoid Receptor Antagonists - therapeutic use | Cardiovascular Agents - therapeutic use | Heart Failure - classification | Defibrillators, Implantable | Cardiovascular Diseases - mortality | Female | Aged | Spironolactone - analogs & derivatives | Spironolactone - therapeutic use | Spironolactone - adverse effects | Heart Failure - mortality | Heart failure | Diagnosis | Drug therapy | Risk factors | Hospitalization | Heart attacks | Statistical analysis | Cardiovascular Diseases/mortality | Cardiovascular Agents/therapeutic use | Aldosterone Antagonists/adverse effects/therapeutic use | Implantable | Kardiologi | Heart Failure/classification/drug therapy/mortality | Cardiac and Cardiovascular Systems | Spironolactone/adverse effects/analogs & derivatives/therapeutic use | Defibrillators | Hospitalization/statistics & numerical data
Journal Article
Circulation, ISSN 0009-7322, 10/2007, Volume 116, Issue 13, pp. 1482 - 1487
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 05/2006, Volume 47, Issue 10, pp. 1997 - 2004
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9744, pp. 886 - 894
Summary Background Raised resting heart rate is a marker of cardiovascular risk. We postulated that heart rate is also a risk factor for cardiovascular events... 
Internal Medicine | RATE REDUCTION | HUMAN MYOCARDIUM | MEDICINE, GENERAL & INTERNAL | SYSTOLIC DYSFUNCTION BEAUTIFUL | CARDIOVASCULAR-DISEASE | DOUBLE-BLIND | ATHEROSCLEROSIS | CORONARY-ARTERY-DISEASE | BETA-BLOCKER | IVABRADINE | LEFT-VENTRICULAR FUNCTION | Benzazepines - adverse effects | Humans | Middle Aged | Heart Failure - physiopathology | Male | Sinoatrial Node - drug effects | Heart Rate - drug effects | Electrocardiography | Adult | Female | Heart Failure - mortality | Severity of Illness Index | Heart Failure - complications | Cardiovascular Agents - administration & dosage | Double-Blind Method | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Heart Failure - drug therapy | Cardiovascular Agents - therapeutic use | Benzazepines - therapeutic use | Aged | Benzazepines - administration & dosage | Cardiovascular Agents - adverse effects | Chronic Disease | Heart failure | Prevention | Heart beat | Dosage and administration | Drug therapy | Health aspects | Risk factors | Cardiovascular agents | Studies | Heart rate | Cardiovascular disease | Mortality | Cardiovascular diseases | use | Sinoatrial Node/drug effects | Heart Failure/complications/drug therapy/mortality/physiopathology | Kardiologi | Cardiac and Cardiovascular Systems | Benzazepines/administration & dosage/adverse effects/therapeutic use | Heart Rate/drug effects | Cardiovascular Agents/administration & dosage/adverse effects/therapeutic | Kaplan-Meiers Estimate
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 07/2007, Volume 50, Issue 1, pp. 40 - 47
Journal Article
JAMA, ISSN 0098-7484, 03/2007, Volume 297, Issue 12, pp. 1319 - 1331
Journal Article
European Heart Journal, ISSN 0195-668X, 07/2004, Volume 25, Issue 14, pp. 1214 - 1220
Journal Article
Circulation, ISSN 0009-7322, 06/2007, Volume 115, Issue 24, pp. 3111 - 3120
Journal Article
Circulation: Heart Failure, ISSN 1941-3289, 01/2016, Volume 9, Issue 1
Background The prevalence of pre-diabetes mellitus and its consequences in patients with heart failure and reduced ejection fraction are not known. We... 
heart failure | Clinical trial | diabetes mellitus | prognosis | treatment outcome | clinical trial | CARDIAC & CARDIOVASCULAR SYSTEMS | PREDICTOR | TOLERANCE | HEMOGLOBIN A(1C) | HOSPITALIZATION | INHIBITION | A1C | INSULIN-RESISTANCE | GLUCOSE | DYSFUNCTION | OUTCOMES | Diabetes Mellitus - blood | Single-Blind Method | Prevalence | Prospective Studies | Ventricular Function, Left | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Heart Failure - physiopathology | Aminobutyrates - adverse effects | Male | Heart Failure - blood | Aminobutyrates - therapeutic use | Enalapril - therapeutic use | Enalapril - adverse effects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Time Factors | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Female | Heart Failure - diagnosis | Diabetes Mellitus - diagnosis | Diabetes Mellitus - mortality | Prediabetic State - epidemiology | Heart Failure - mortality | Prediabetic State - blood | Risk Assessment | Comorbidity | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Biomarkers - blood | Heart Failure - drug therapy | Prediabetic State - mortality | Prediabetic State - diagnosis | Stroke Volume | Disease-Free Survival | Diabetes Mellitus - epidemiology | Tetrazoles - therapeutic use | Aged | Tetrazoles - adverse effects | Blood Glucose - metabolism | Angiotensin Receptor Antagonists - therapeutic use | Drug Combinations | Angiotensin Receptor Antagonists - adverse effects | 10093 | 10150 | 10094 | Original | glucose | hospitalization | inhibition | Klinisk medicin | dysfunction | Clinical Medicine | a1c | insulin-resistance | hemoglobin a(1c) | Cardiovascular System & Cardiology | predictor | cardiovascular risk | tolerance
Journal Article